TRCT
STOK icon

Tower Research Capital (TRC)’s Stoke Therapeutics STOK Stock Holding History

Tower Research Capital (TRC)’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.9K Sell
2,290
-2,137
-48% -$68.6K ﹤0.01% 2413
2026
Q1 		$144K Buy
4,427
+3,797
+603% +$125K ﹤0.01% 1888
2025
Q4 		$20K Sell
630
-530
-46% -$15.9K ﹤0.01% 3101
2025
Q3 		$27.3K Sell
1,160
-3,210
-73% -$55K ﹤0.01% 3035
2025
Q2 		$49.6K Buy
4,370
+3,591
+461% +$34.1K ﹤0.01% 2977
2025
Q1 		$5.18K Sell
779
-11,151
-93% -$104K ﹤0.01% 4146
2024
Q4 		$132K Buy
11,930
+4,918
+70% +$60.4K ﹤0.01% 1996
2024
Q3 		$86.2K Buy
7,012
+2,994
+75% +$42.4K ﹤0.01% 2339
2024
Q2 		$54.3K Buy
4,018
+1,357
+51% +$18.3K ﹤0.01% 3040
2024
Q1 		$35.9K Sell
2,661
-2,378
-47% -$14.4K ﹤0.01% 2501
2023
Q4 		$26.5K Buy
5,039
+1,298
+35% +$5.55K ﹤0.01% 3489
2023
Q3 		$14.7K Sell
3,741
-942
-20% -$6.19K ﹤0.01% 3660
2023
Q2 		$49.8K Buy
4,683
+390
+9% +$4.15K ﹤0.01% 2589
2023
Q1 		$36K Sell
4,293
-30,200
-88% -$272K ﹤0.01% 2817
2022
Q4 		$319K Buy
34,493
+31,094
+915% +$323K 0.01% 975
2022
Q3 		$44K Sell
3,399
-1,376
-29% -$21.9K ﹤0.01% 3289
2022
Q2 		$63K Sell
4,775
-4,285
-47% -$65.1K ﹤0.01% 2675
2022
Q1 		$190K Buy
9,060
+5,925
+189% +$119K ﹤0.01% 1766
2021
Q4 		$75K Buy
3,135
+1,569
+100% +$37.4K ﹤0.01% 2440
2021
Q3 		$40K Sell
1,566
-5,969
-79% -$166K ﹤0.01% 3132
2021
Q2 		$254K Buy
7,535
+5,982
+385% +$211K 0.01% 1745
2021
Q1 		$60K Sell
1,553
-446
-22% -$25.4K ﹤0.01% 2974
2020
Q4 		$124K Sell
1,999
-5,232
-72% -$240K ﹤0.01% 2147
2020
Q3 		$243K Buy
7,231
+2,527
+54% +$72.2K ﹤0.01% 2389
2020
Q2 		$112K Buy
+4,704
New +$112K ﹤0.01% 2359

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tower Research Capital (TRC)'s STOK Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Stoke Therapeutics (STOK) stake by 48% in Q2 2026, selling an estimated $68.6K and leaving 2,290 shares worth $74.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2413.

Tower Research Capital (TRC) first reported a position in STOK in Q2 2020 and has held it in 25 quarters since. The position peaked at $319K in Q4 2022. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Tower Research Capital (TRC) held 2,290 shares of Stoke Therapeutics worth $74.9K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,137 Stoke Therapeutics shares in Q2 2026, an estimated $68.6K.
  • Stoke Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2413 holding.
  • Tower Research Capital (TRC) first reported a position in Stoke Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Stoke Therapeutics position peaked at $319K in Q4 2022.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.